Hanmi Pharmaceutical’s Amozaltan XQ, the world's first four-ingredient combination drug for hypertension and dyslipidemia, received positive reviews from medical specialists at an online conference hosted by the Korean Society of Hypertension.

“More than half of hypertension patients have dyslipidemia, which makes an integrated treatment and management to reduce the incidence of cardiovascular disease very important,” Korea University College of Medicine Cardiology Professor Park Seong-mi said at the meeting attended by about 200 cardiologists and vascular specialists.

Recent studies show that treating both blood pressure and low-density lipoprotein-cholesterol (LDL-C) gives clinical benefit and also emphasize the need to raise patient compliance with combination drug, Park said.

Amozaltan XQ has effectively lowered blood pressure and reduced LDL-C by about 60 percent compared to baseline, with excellent patient compliance, in phase 3 clinical trials conducted in Korea. Amozaltan XQ could be a therapeutic option for patients who need to control blood pressure and LDL-C level simultaneously, Park added.

CHA Gangnam Medical Center Professor Kim Jong-jin also said, “It is noteworthy that the Amozaltan series continue to show clinical benefits in various studies conducted on domestic patients, such as The K-Central Study announced in 2019.” 

A Hanmi official stressed that the Amozaltan series is an optimal combination drug for treating hypertension and dyslipidemia. The company will continue to show more useful study results to health providers and release new products that could be of real help to the clinical field, the official added.

Hanmi Pharmaceutical marked 116.5 billion won ($104.3 million) in outpatient prescription sales last year, up 12 percent from 2019. The company dominated the calcium channel blocker (CCB)-angiotensin receptor blocker (ARB) combo therapy market for two consecutive years, thanks to the continued growth of the Amozaltan series.